ClinicalTrials.gg
Not yet recruitingNCT07382427Updated Feb 4, 2026

A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails

A Phase 2 interventional study of 2.4% Topical Terbinafine and 10% Topical Efinaconazole in Onychomycosis of Toenail, sponsored by Onyx Axiom. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Onyx Axiom · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.

Planned enrollment
8th of 19
200 · median 100
Started
2026
the only one that year
Phase 2
5 of 20
1 open now
Registered
20th of 20
by date
Lead sponsor
1 of 20
Onyx Axiom

Among the 20 studies testing terbinafine in Onychomycosis, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, and was the 20th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

1 of the 20 studies testing terbinafine in Onychomycosis is open now.

About terbinafine

Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing terbinafine in Onychomycosis, or all of them as a file.
02

Study summary

Onychomycosis is a fungal infection of the toenail caused by a range of organisms, including dermophytes, non-dermophyte molds, and yeasts. Topical antifungals are often used for mild to moderate onychomycosis, especially when oral therapy is contraindicated. Generally, topical antifungal agents are well-tolerated with minimal side effects, but they are less effective than oral antifungal therapies due to poor nail penetration. Consequently, the current treatment period for topical onychomycosis products is \~12 months.

Terbinafine is an antifungal drug approved by the FDA for the treatment of topical skin infections. A new formulation (AP4500) has been developed to increase terbinafine absorption through the nail in order to directly kill fungi at the site of onychomycosis infection.

The goal of this clinical trial is to learn if AP4500 works to treat mild to moderate toenail fungus in adults. The main questions the study aims to answer are:

Does AP4500 work to treat onychomycosis? Does AP4500 work best when applied once or twice per day? Does AP4500 treat onychomycosis faster than current treatments? Is AP4500 more effective than current treatments?

Researchers will compare AP4500 to a vehicle control (a look-alike substance that contains no drug) and a commercial comparator product (Jublia) that has already been commercialized for the treatment of toenail fungus.

Participants will:

Apply topical formulations once or twice a day to an infected toenail for a period of 48 weeks Visit the clinic 4 times over this period for checkups and tests, with a subsequent follow up visit 4 weeks after treatment is completed

03

Conditions studied

  • Onychomycosis of Toenail

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 to 70 years, inclusive at the time of .
  • In general, good health, as assessed by the Investigator, as determined by medical history, safety laboratory tests, and other tests.
  • At least 1 great toenail (the "target great toenail") with clinically diagnosed distal lateral subungual onychomycosis involving 20% to 50% of the affected great toenail but with no more than 6 toenails and no fingernails involved, and without dermatophytomas or lanula (matrix) involvement.
  • Target great toenail must have an uninfected length of at least 3 mm from the proximal nailfold and a thickness of no more than 3 mm.
  • Target great toenail must have evidence of toenail growth per the participant's report that monthly clipping is required.
  • Within 42 days prior to Baseline (Day 1), must have a positive potassium hydroxide (KOH) examination of the target great toenail.
  • Within 42 days prior to Baseline (Day 1), must have a positive dermatophyte culture for Trichophyton rubrum or Trichophyton mentagrophytes from the target great toenail.
  • Women of (WOCBP) must have a negative pregnancy test at Screening and prior to dosing and be willing to have additional pregnancy tests as required throughout the trial. Women not of childbearing potential are women who are either permanent sterile or . Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Postmenopausal status will be confirmed through testing of follicle-stimulating hormone (FSH) levels ≥40 IU/L at Screening for amenorrheic female participants.
  • Agree to avoid the use of toenail polish, cosmetic toenail products, and pedicures during the trial period.
  • Written informed consent from the participant prior to any trial procedures.
  • Willing and able to comply with the scheduled visits, confinement period, treatment plan, laboratory tests, and other trial procedures and requirements.

Exclusion criteria

Exclusion Criteria:

  • Presence of any toenail infection other than or in addition to dermatophytes, such as Scytalidium as determined by the Investigator (candidal onychomycosis infection, concurrent with a positive dermatophyte culture, is acceptable).
  • Presence of any of the following: dermatophytoma, fungal "spikes" within 3 mm of the proximal toenail fold on the target great toenail, infection extending to the matrix, or only lateral toenail disease in the target great toenail.
  • Presence of severe moccasin tinea pedis at the Screening or Baseline visits, as determined by the Investigator. If the participant has interdigital tinea pedis that requires treatment, the participant must agree to use only an Investigator-approved topical antifungal therapy .
  • Presence of any disease/condition that might cause toenail abnormalities or may interfere with the evaluation of the medicinal product (IMP), as determined by the Investigator (e.g., open sore or ulceration on the toes of affected toenails, psoriasis, immune dysfunction , collagen-vascular diseases, lichen planus, peripheral vascular disease, recurrent cellulitis, lymphatic insufficiency, or traumatic onychodystrophy due to chronic physical stimuli).
  • Any previous surgery on the target great toenail.
  • Presence of onychomycosis of the fingernail or fingernail dermatophytosis.
  • Target great toenail (including the toenail plate and any subungual debris) thicker than 3 mm at the Screening and Baseline visit - Day 1s.
  • Presence of onychodystrophy that could interfere with clinical assessments, as determined by the Investigator.
  • Presence of any underlying disease or dermatological condition that, in the opinion of the Investigator, could present a safety concern for the participant or that could interfere with clinical evaluations.
  • Use of the following topical preparations within the indicated time prior to the Baseline visit (Day 1) or need for concurrent use of any of the following topical preparations during the trial; Toenail polish or cosmetic toenail products: 1 day; Other topical prescription or over-the-counter medications to the toenails (with the exception of bland emollients): 2 weeks; Topical prescription or over-the-counter antifungal therapy for the toenails, including devices to treat onychomycosis: 4 weeks
  • Use of the following systemic medications within the indicated time prior to the Baseline visit or need for concurrent use of any of the following systemic medications during the trial; Systemic antifungal therapy: 4 weeks; Systemic immunosuppressive agents: 6 months; History of oral antifungal with known activity against dermatophytes within twelve months prior to Screening.
  • Known (HIV) infection self-reported or as determined by the Investigator.
  • Received treatment for any type of cancer in the previous 6 months, with the exception of nonmelanoma skin cancer (e.g., basal cell carcinoma or nonmetastatic squamous cell carcinoma) that was treated successfully .
  • Diagnosis of diabetes mellitus.
  • History of or allergic reactions to any of the IMP constituents.
  • Females who are pregnant, lactating, or planning a pregnancy during the trial period.
  • History of immunosuppression and/or clinical signs indicative of possible immunosuppression, as determined by the Investigator.
  • History of drug abuse or addiction in the last 12 months of enrolment that, in the opinion of the Investigator, could affect the participant's safety and/or compliance with the trial .
  • History of alcohol abuse that, in the opinion of the Investigator, could affect the participant's safety and/or compliance with the trial. As per Australian Alcohol Guidelines, Australian Government it is recommended regular consumption of more than 10 standard drinks/week and/or no more than 4 standard drinks on any single day, where 1 standard drink is 10 g of pure alcohol and is equivalent to 285mL beer (4.9% alcohol/volume), 100 mL wine (12% alcohol/volume) or 30 mL spirit (40% alcohol/volume).

Use of any investigational drug or device within 30 days of 5 half-lives (whichever is longer) prior to the Screening visit or concurrent participation in another clinical trial with an investigational drug or device.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    2.4% Topical Terbinafine once per day

    Novel topical terbinafine formulation developed to increase drug absorption through the nail. Applied once per day.

    Drug: 2.4% Topical Terbinafine

  • Experimental
    2.4% Topical Terbinafine twice per day

    Novel topical terbinafine formulation developed to increase drug absorption through the nail. Applied twice per day.

    Drug: 2.4% Topical Terbinafine

  • Active comparator
    10% Topical Efinaconazole once per day

    Commercial comparator product approved for the treatment of onychomycosis. Applied once per day, as per labelled instructions.

    Drug: 10% Topical Efinaconazole

  • Placebo comparator
    Topical Vehicle once per day

    Vehicle formulation without drug to act as control group for the experimental product. Applied once per day.

    Other: Vehicle Control

  • Placebo comparator
    Topical Vehicle twice per day

    Vehicle formulation without drug to act as control group for the experimental product. Applied twice per day.

    Other: Vehicle Control

Interventions

  • Novel topical terbinafine product designed to increase terbinafine absorption through the nail to the site of infection

  • Commercial topical efinaconazole formulation approved for the treatment of onychomycosis

  • OtherVehicle Control

    Vehicle control formulation to act as a control for the experimental product

06

What researchers measure

Primary outcomes

  1. Number of patients with Complete Cure at Weeks 12, 24, 36, 48, and 52

    Complete Cure is defined as 0% visible onychomycosis of the target great toenail upon examination and negative potassium hydroxide \[KOH\] fungal culture

    Time frame: 52 weeks

Secondary outcomes

  1. Number of participants with Almost Complete Cure at Weeks 12, 24, 36, 48 and 52

    Almost Complete Cure defined as onychomycosis affecting a maximum of 5% toenail after visual examination and negative KOH examination and fungal culture

    Time frame: 52 weeks

  2. Incidence, severity, and relationship to treatment of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) as coded by MedDRA

    A by participate adverse event data listing, including verbatim term, preferred term, system organ class, severity, and relationship to the investigational medicinal product are to be provided.

    Time frame: 52 weeks

  3. Time to Clinical Efficacy in participants over 48 weeks

    Affected toenails will be visually assessed at 12, 24, 36, 48 and 52 weeks for Clinical Efficacy (defined as a maximum of 10% of the nail demonstrating onychomycosis)

    Time frame: 52 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — This is an industry sponsored trial using a proprietary formulation. Results will be commercially confidential.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jan 2028, 22 months later.

Of 16 phase 2 interventional studies under Onychomycosis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 22. This study's planned 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Feb 2, 2026
StartEst.
Mar 2026
Primary completionEst.
Jan 2028
CompletionEst.
Feb 2028
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07382427
Lead sponsor
Onyx Axiom
Responsible party
Sponsor
First posted
Feb 2, 2026
Start date
Mar 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Feb 4, 2026

Study contacts

Dianne Pepper
Contact
dianne.pepper@alithialifesciences.com
+61426762990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion